Health Disparities & sCD40L: Novel Biomarkers for HIV-1 Disease Progression

健康差异

• 批准号: 8511818
• 负责人: Anuja Ghorpade
• 金额: $ 18.46万
• 依托单位: UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-15 至 2017-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8511818
• 关键词: Acquired Immunodeficiency Syndrome; Address; Affect; African American; Area; Basic Science; Biological Markers; Blood specimen; Body Composition; Brain; CD4 Lymphocyte Count; CD4 Positive T Lymphocytes; CD40 Ligand; Caucasians; Caucasoid Race; Cell Count; Cell Separation; Cells; Clinic; Clinical; Clinical Research; Cognitive; Color; Communicable Diseases; Communities; Data; Diagnosis; Disease; Disease Progression; Dyslipidemias; Evaluation; Face; Feminization; Future; Gender; HIV; HIV-1; Health education; Heterosexuals; Hispanic Americans; Hypertriglyceridemia; Immune; Impaired cognition; Impairment; Individual; Instruction; International; Knowledge; Lead; Leukocytes; Life; Lipids; Measures; Membrane Glycoproteins; Metabolic; Minority; Monitor; Neurocognitive; Neurologic; Neurologic Manifestations; Outcome; Outreach Research; Patients; Pattern; Plasma; Plasma Cells; Population Characteristics; Prognostic Marker; Protease Inhibitor; Quality of Care; Questionnaires; RNA; Race; Recording of previous events; Recruitment Activity; Research; Risk Factors; Role; Sampling; Sex Characteristics; Surrogate Markers; TNF gene; TNFSF5 gene; Testing; Texas; Therapeutic; Time; United States; Viral Load result; Woman; Women' s Health; Work; antiretroviral therapy; base; burden of illness; caucasian American; cognitive function; cohort; computerized; cytokine; demographics; disease characteristic; health disparity; immune activation; injection drug use; leukocyte activation; men; minority health; novel; pandemic disease; racial and ethnic; racial difference; socioeconomics; transmission process; trend

Woridwide, -40 million people live with Human Immunodeficiency Virus (HIV)-I disease and associated Acquired Immune Deficiency Syndrome (AIDS), half are women. HIV/AIDS has affected more women than any other disease over the past two decades. Women of color, particularly, African American and Hispanic American women carry the most significant burden of this disease. Clearly, HIV/AIDS in minorities and women will continue to be a significant burden and a critical area of Health Disparities research. Importantly, almost 50% of HIV/AIDS patients suffer from some neurocognitive impairment. Thus, studies that pertain to identification of novel biomarkers that predict disease progression and neurocognitive impairment are critical. Recent data demonstrate that sCD40L, a novel biomarker is significantly elevated in HIV-infected patients with neurocognitive impairment. However, no information is available regarding patterns of sCD40L changes in context of race and gender. This is important, as expression of disease characteristics in HIV/AIDS can be race- and/or gender-specific. Viral loads, metabolic parameters and body composition, plasma lipid levels etc. differ in the setting of specific race and gender. In this application, we propose to investigate the role of SCD40L as a prognostic marker for disease progression in HIV-1 neurological manifestations in the context of race and gender. Although limited to evaluations of race and gender as statistical risk factors, this work will synergize basic science with issues related to health disparities. Specifically, we will identify and analyze plasma sCD40L levels in a cohort of HIV+/- patients and correlate these to standard disease variables and cognitive function. All parameters will be correlated with each other and against neurocognitive measures to test the hypothesis that sCD40L levels correlate with neurocognitive impairment in the context of race and gender. We will also analyze the immune activation status of diverse patient leukocytes. Levels of sCD40L & other proinflammatory cytokines including TNF-a will be analyzed. Ours will be one ofthe first studies to fully describe the HIV-1-positive population characteristics in relation to specific cognitive outcomes, socioeconomic strata and sCD40L and will likelv vield data that will have direct therapeutic implications.

全球范围内，-4000 万人患有人类免疫缺陷病毒 (HIV)-I 疾病及相关疾病 患有获得性免疫缺陷综合症（艾滋病）的人中有一半是女性。艾滋病毒/艾滋病影响的女性人数超过 过去二十年中任何其他疾病。有色人种女性，特别是非裔美国人和西班牙裔女性 美国女性承受着这种疾病的最沉重负担。显然，艾滋病毒/艾滋病在少数群体和 妇女将继续成为健康差异研究的重大负担和关键领域。重要的是， 近 50% 的艾滋病毒/艾滋病患者患有某种神经认知障碍。因此，有关的研究 识别预测疾病进展和神经认知障碍的新型生物标志物至关重要。 最近的数据表明，sCD40L（一种新型生物标志物）在 HIV 感染患者中显着升高 患有神经认知障碍。然而，没有关于 sCD40L 变化模式的信息 在种族和性别的背景下。这很重要，因为艾滋病毒/艾滋病疾病特征的表达可以 种族和/或性别特定。病毒载量、代谢参数和身体成分、血浆脂质水平 等因特定种族和性别的设置而异。在此应用中，我们建议研究 SCD40L 作为 HIV-1 神经系统表现疾病进展的预后标志物 种族和性别。尽管仅限于将种族和性别作为统计风险因素进行评估，但这项工作 将基础科学与健康差异相关问题结合起来。具体来说，我们将识别并分析 一组 HIV+/- 患者的血浆 sCD40L 水平，并将其与标准疾病变量相关联 认知功能。所有参数都将相互关联并与神经认知测量相关 检验 sCD40L 水平与种族背景下的神经认知障碍相关的假设 性别。我们还将分析不同患者白细胞的免疫激活状态。 sCD40L 的水平 & 将分析包括 TNF-a 在内的其他促炎细胞因子。我们的研究将是第一个充分研究 描述与特定认知结果相关的 HIV-1 阳性人群特征， 社会经济阶层和 sCD40L 并将喜欢具有直接治疗意义的数据。